Medirom Healthcare Technologies Inc. Reports Strong July 2025 KPIs with High Sales Per Customer and Increased App Users

Reuters
08/20
Medirom Healthcare Technologies Inc. Reports Strong July 2025 KPIs with High Sales Per Customer and Increased App Users

MEDIROM Healthcare Technologies Inc., a holistic healthcare company based in Japan and listed on Nasdaq, has reported its key performance indicators for July 2025. The company served a total of 76,544 customers, with sales per customer averaging JPY 7,389. The customer repeat ratio stood at 77.0%. In its Salon Operation Business, MEDIROM noted that the sales per customer remain high at ¥7,389, which is approximately ¥2,583 above the previous figures. In the Health Tech Business segment, which includes the Lav® on-demand training application, MEDIROM has entered into contracts with 101 corporate insurance associations. The cumulative number of users of the Lav® app has exceeded 10,000 people, totaling 10,842 individuals. This segment is expected to grow due to the increased adoption of Information and Communication Technology (ICT) in health guidance programs, partly driven by the impact of COVID-19. The company aims to meet the nationwide target set by Japan's Ministry of Health, Labor and Welfare for specific medical checkup and guidance implementation rates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medirom Healthcare Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-011682), on August 20, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10